| Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia. | |
| | |
MedLine Citation:
|
PMID: 19441109 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Therapy related secondary acute myelogenous leukemia (AML) was commonly associated with prior exposure to alkylating agents or topoisomerase inhibitor. The long-term outcome of such patients with secondary AML was found to be worse than that of patients with de novo AML. Earlier reports suggested similar outcomes for patients with de novo and secondary AML associated with core-binding factor (CBF) abnormalities. METHODS: A total of 188 patients with CBF AML were analyzed. The frequency of secondary CBF AML was 9%. RESULTS: Patients with secondary CBF AML were found to have significantly worse overall (OS) and event-free survival (EFS) compared with patients with de novo CBF AML. Secondary CBF AML status appeared to have only marginal significance in multivariate analysis. CONCLUSIONS: Matched analysis (by age, Eastern Cooperative Oncology Group performance status, and additional cytogenetic abnormality) indicated worse OS and EFS in patients with secondary CBF AML. |
| | |
Authors:
|
Gautam Borthakur; E Lin; Nitin Jain; Elihu E Estey; Jorge E Cortes; Susan O'Brien; Stefan Faderl; Farhad Ravandi; Sherry Pierce; Hagop Kantarjian |
Related Documents
:
|
6932649 - Defibrination in adult acute lymphoblastic leukaemia. report of four cases. 6118669 - Therapeutic selectivity of and predication of response to 2'-deoxycoformycin in acute l... 6192899 - Red cell aplasia in myelofibrosis with myeloid metaplasia. a distinct functional and cl... 8722369 - Polymerase chain reaction is highly predictive of relapse in patients following t cell-... 2293879 - Results of chromosome studies and their relation to morphology, course, and prognosis i... 2673329 - Unusual immunophenotypes in acute leukaemias: incidence and clinical correlations. 2884999 - Partial deficiency of subunits in complex i or iv of patients with mitochondrial myopat... 19144299 - Immunologic evaluation of patients with recurrent ear, nose, and throat infections. 23140269 - The inflammatory biomarker ykl-40 at admission is a strong predictor of overall mortality. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Cancer Volume: 115 ISSN: 0008-543X ISO Abbreviation: Cancer Publication Date: 2009 Jul |
Date Detail:
|
Created Date: 2009-07-10 Completed Date: 2009-08-17 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0374236 Medline TA: Cancer Country: United States |
Other Details:
|
Languages: eng Pagination: 3217-21 Citation Subset: AIM; IM |
Affiliation:
|
Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA. gborthak@mdanderson.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Aged, 80 and over Core Binding Factors / metabolism* Cytarabine / therapeutic use Disease-Free Survival Female Humans Leukemia, Myeloid, Acute / drug therapy, genetics, mortality* Male Middle Aged Neoplasms, Second Primary / mortality* Survival Analysis Translocation, Genetic |
| Chemical | |
Reg. No./Substance:
|
0/Core Binding Factors; 147-94-4/Cytarabine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Targeting heat shock protein 90 with non-quinone inhibitors: a novel chemotherapeutic approach in hu...
Next Document: Number of metastatic sites is a strong predictor of survival in patients with nonsmall cell lung can...